- Home
- INKT vs ICCC Comparison
INKT vs ICCC Comparison
Compare INKT & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INKT
- ICCC
- Stock Information
- Founded
- INKT 2017
- ICCC 1982
- Country
- INKT United States
- ICCC United States
- Employees
- INKT N/A
- ICCC N/A
- Industry
- INKT Medicinal Chemicals and Botanical Products
- ICCC Biotechnology: Pharmaceutical Preparations
- Sector
- INKT Health Care
- ICCC Health Care
- Exchange
- INKT Nasdaq
- ICCC Nasdaq
- Market Cap
- INKT 33.6M
- ICCC 39.2M
- IPO Year
- INKT 2021
- ICCC 1987
- Fundamental
- Price
- INKT $9.03
- ICCC $5.01
- Analyst Decision
- INKT Strong Buy
- ICCC
- Analyst Count
- INKT 2
- ICCC 0
- Target Price
- INKT $37.50
- ICCC N/A
- AVG Volume (30 Days)
- INKT 10.5K
- ICCC 10.9K
- Earning Date
- INKT 03-18-2025
- ICCC 05-13-2025
- Dividend Yield
- INKT N/A
- ICCC N/A
- EPS Growth
- INKT N/A
- ICCC N/A
- EPS
- INKT N/A
- ICCC N/A
- Revenue
- INKT N/A
- ICCC $26,493,000.00
- Revenue This Year
- INKT N/A
- ICCC N/A
- Revenue Next Year
- INKT N/A
- ICCC N/A
- P/E Ratio
- INKT N/A
- ICCC N/A
- Revenue Growth
- INKT N/A
- ICCC 51.63
- 52 Week Low
- INKT $4.56
- ICCC $3.34
- 52 Week High
- INKT $19.00
- ICCC $5.82
- Technical
- Relative Strength Index (RSI)
- INKT 53.66
- ICCC 51.19
- Support Level
- INKT $7.81
- ICCC $4.56
- Resistance Level
- INKT $9.23
- ICCC $5.05
- Average True Range (ATR)
- INKT 0.85
- ICCC 0.26
- MACD
- INKT 0.11
- ICCC 0.01
- Stochastic Oscillator
- INKT 68.66
- ICCC 89.02
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T-cell therapies to treat cancer and other life-threatening illnesses.
About ICCC ImmuCell Corporation
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.